[HTML][HTML] A randomized study of alglucosidase alfa in late-onset Pompe's disease
…, RT Leshner, JE Mayhew, C Morgan… - … England Journal of …, 2010 - Mass Medical Soc
Background Pompe's disease is a metabolic myopathy caused by a deficiency of acid alpha
glucosidase (GAA), an enzyme that degrades lysosomal glycogen. Late-onset Pompe's …
glucosidase (GAA), an enzyme that degrades lysosomal glycogen. Late-onset Pompe's …
Influence of storage on red blood cell rheological properties
TL Berezina, SB Zaets, C Morgan, CR Spillert… - Journal of surgical …, 2002 - Elsevier
Background. It is known that the age of transfused blood is a risk factor for the development
of multiple organ failure in surgical patients. However, the character of hemorrheological …
of multiple organ failure in surgical patients. However, the character of hemorrheological …
[HTML][HTML] Population genomics reveal recent speciation and rapid evolutionary adaptation in polar bears
Polar bears are uniquely adapted to life in the High Arctic and have undergone drastic
physiological changes in response to Arctic climates and a hyperlipid diet of primarily marine …
physiological changes in response to Arctic climates and a hyperlipid diet of primarily marine …
[HTML][HTML] Early treatment with alglucosidase alfa prolongs long-term survival of infants with Pompe disease
…, MS Bauer, M Jokic, CE Tsai, BWH Tsai, C Morgan… - Pediatric …, 2009 - nature.com
In a previous 52-wk trial, treatment with alglucosidase alfa markedly improved cardiomyopathy,
ventilatory function, and overall survival among 18 children< 7 mo old with infantile-onset …
ventilatory function, and overall survival among 18 children< 7 mo old with infantile-onset …
[HTML][HTML] Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease
…, S Kimura, L Mehta, D Bali, A Skrinar, C Morgan… - Genetics in …, 2009 - nature.com
Purpose: A clinical trial was conducted to evaluate the safety and efficacy of alglucosidase
alfa in infants and children with advanced Pompe disease. Methods: Open-label, multicenter …
alfa in infants and children with advanced Pompe disease. Methods: Open-label, multicenter …
Immunosensors: technology and opportunities in laboratory medicine
CL Morgan, DJ Newman, CP Price - Clinical chemistry, 1996 - academic.oup.com
An immunosensor is a device comprising an antigen or antibody species coupled to a
signal transducer, which detects the binding of the complementary species. An indirect …
signal transducer, which detects the binding of the complementary species. An indirect …
Human pancreatic islet three-dimensional chromatin architecture provides insights into the genetics of type 2 diabetes
Genetic studies promise to provide insight into the molecular mechanisms underlying type 2
diabetes (T2D). Variants associated with T2D are often located in tissue-specific enhancer …
diabetes (T2D). Variants associated with T2D are often located in tissue-specific enhancer …
[PDF][PDF] Changes in the coding and non-coding transcriptome and DNA methylome that define the Schwann cell repair phenotype after nerve injury
PJ Arthur-Farraj, CC Morgan, M Adamowicz… - Cell reports, 2017 - cell.com
Repair Schwann cells play a critical role in orchestrating nerve repair after injury, but the
cellular and molecular processes that generate them are poorly understood. Here, we perform a …
cellular and molecular processes that generate them are poorly understood. Here, we perform a …
Cardiovascular risk perception and evidence–practice gaps in Australian general practice (the AusHEART study)
Objective: To examine the perception and management of cardiovascular disease (CVD)
risk in Australian primary care. Design, setting and participants: The Australian Hypertension …
risk in Australian primary care. Design, setting and participants: The Australian Hypertension …
The prevalence of weekly angina among patients with chronic stable angina in primary care practices: The Coronary Artery Disease in General Practice (CADENCE) …
JF Beltrame, AJ Weekes, C Morgan… - Archives of Internal …, 2009 - jamanetwork.com
Background Angina, the cardinal symptom of coronary artery disease (CAD), is amenable to
a range of therapies, and its routine assessment is considered a performance measure of …
a range of therapies, and its routine assessment is considered a performance measure of …